Caricamento...

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends thos...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Vaccine Immunol
Autori principali: Chen, Wilbur H., Jackson, Lisa A., Edwards, Kathryn M., Keitel, Wendy A., Hill, Heather, Noah, Diana L., Creech, C. Buddy, Patel, Shital M., Mangal, Brian, Kotloff, Karen L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2016
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4711091/
https://ncbi.nlm.nih.gov/pubmed/26561390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00475-15
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !